EUVIMEDEUVIMED entdecken
Crossref

Looking Beyond Metastasis to Explain Cancer Death

Lizzy Galamba

Oncology Times · 2026-03 · 48 (3) · 15-15

DOI: 10.1097/01.cot.0000000000000307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Times, online erschienen am 25.02.2026. Verfasst von Lizzy Galamba.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research has long since discovered the origin of cancer but has failed to understand the biological mechanisms that cause cancer-related deaths. For decades, cancer deaths were attributed to metastatic disease, a weakened immune system, and sepsis. However, University of Texas Southwestern and ETH Zurich researchers are refusing to accept these beliefs as law. In a first-of-its-kind study, researchers and clinicians are teaming up to understand the cause of death in cancer patients to inform treatment options, enhance quality of life, and prolong survival for patients with advanced cancers. “If we hope to cure cancer—or even turn it into a chronic condition that people can live with for many years—we must first understand it,” said Matteo Ligorio, MD, PhD, Assistant Professor of Surgery at the Harold C. Simmons Comprehensive Cancer Center. “Why do patients with cancer die? This is the central question, and until we address that, we will not be able to fully understand what makes cancer a life-incompatible condition.” Patients can live with metastatic disease for years before a sudden decline. Ligorio, questioning the cause of this change, looked at previous studies that showed cancer patients are more likely to develop blood clots, indicating the central role of the cardiovascular system in tumor progression. He hypothesized that the infiltration and colonization of major arteries and veins, as well as the formation of large circulating tumor cell clusters, may be the source of these clots, which often lead to organ failure. Ligorio then brought this idea to Kelley Newcomer, MD, Associate Professor of Internal Medicine at UT Southwestern and a hospice and palliative medicine physician. “I have been doing hospice for about 20 years and have watched a lot of patients die, and I really thought most cancer patients were passing away as a result of infection,” Newcomer said. “We actually had a large cohort of patients at Parkland and UT Southwestern who had died from cancer in the hospital and then received an autopsy. We had over 100 patients who had a cancer diagnosis and died over a 10-year period. When I went through all their charts, I thought, ‘I'm still not exactly sure what happened to these people, but I'm fairly certain it wasn't an infection.’ Consistently, they lacked positive blood cultures and strong evidence of microbial infection.” Newcomer describes this as her “lightbulb moment,” and the study began. The cohort, representing many different cancer types, included 21 hospice and palliative patients with terminal cancer and 10 control patients with other non-cancer diseases. Utilizing the Palliative Performance Scale to determine a patient's condition, blood samples were taken at significant moments of patient-reported decline to determine the presence of circulating tumor cells. Upon the patient's death, Ligorio performed a modified autopsy to keep the vascular system intact and consistently observed an unforeseen, significant change of the walls and interiors of major blood vessels due to the presence of large, tumor-infiltrating masses: macrovascular infiltration. “I reimaged the warm autopsy technique to be precisely tailored to answer our hypothesis, but broad enough to not lose the opportunity to discover if there were confounding factors or other cancer-related factors that would contribute to the patient's death.” Ligorio said. “I found that there are masses that were infiltrating large blood vessels like the inferior vena cava, portal veins, and so on. Then I said, ‘Well, we are observing a perimortem spike in circulatory cells—thanks to our collaboration with Dr. Aceto at ETH Zurich—and have these infiltrating masses. Would they be related?’ Of course, we don't have formal proof that these cells are coming from that site, but several hints point in that direction. We are connecting the dots.” Partnering with the University of Lübeck and the University of Mainz in Germany, as well as the University of Nebraska in Omaha, the UT Southwestern team examined CT images from 1,250 cancer patients across five cancer types. “When we went back and looked, we would see this tumor growing closer and closer to the vessel, invading the vessel, and then we could tell the patient had gone from an organ-centric cancer to a vascular-colonizing tumor,” Newcomer said. “Once macrovascular invasion was present, patients had a few months, irrespective of the presence of metastasis. On the contrary, when patients had distant metastases but no radiological evidence of macrovascular infiltration, even with aggressive tumor diagnosis, such as ovarian, lung, and liver cancer, patients lived for years, making macrovascular infiltration the best predictor of survival.” Researchers believe that this discovery will not only inform treatment but may also revolutionize cancer staging, sparking a possible restaging. However, more clinical research is needed before either can happen. “Right now, we want to do a clinical trial to prove if this correlation turns out to be causation. If it is, it will have a profound impact on patients' lives, because now we can interrupt, mitigate, and prevent what makes cancer incompatible with life,” Ligorio said. “This is a very testable theory. We need to prevent or target macrovascular colonization and observe whether this intervention increases survival.” Ligorio believes the study could have been performed in the 1970s or 1980s, as the methods of discovering and treating some tumor lesions infiltrating large vessels, including CT imaging and surgery, were already available. “The beauty of this is that we don't need to discover a new technique to diagnose vascular-infiltrating lesions. CT and MRI imaging are sufficient, at least for now. Surgery, radiation therapy, or vascular stenting to masses encroaching on major vessels may be enough to understand the effects of macrovascular infiltration on patient status.” Most impressive about this study were the patients and their families. In the final months of their lives, the participating hospice patients displayed remarkable courage and selflessness in their heartbreaking, yet heartwarming, contribution to oncology research and fellow cancer patients. “One thing that I think we're trying to challenge is the idea that for patients who are on hospice, the burden is too great to ask them to participate in research or that their disease is too advanced. As a result, they're excluded from so many opportunities for research,” Newcomer said. “When we could talk to the patient directly, they were very excited, and it really helped them to find meaning in their suffering and in their disease. They're at a time in their life when they're looking back and looking for meaning. I had one woman who had completely untreated breast cancer and had gone straight to hospice. She begged me to be in a study. She told me, ‘If one young woman doesn't get breast cancer as I did from this study, I will feel like this has been worth it to me.’ It was just a privilege to work with these wonderful families.” This study was published in Nature in October 2025 and further reviewed in Nature Medicine in November 2025 (doi.org/10.1038/s41591-025-03966-3). Lizzy Galamba is a contributing writer.

Zitieren

APA

Galamba, L. (2026). Looking Beyond Metastasis to Explain Cancer Death. Oncology Times, 48(3), 15-15. https://doi.org/10.1097/01.cot.0000000000000307

Vancouver

Galamba L. Looking Beyond Metastasis to Explain Cancer Death. Oncology Times. 2026;48(3):15-15. doi:10.1097/01.cot.0000000000000307

BibTeX
@article{Galamba2026,
  author = {Galamba, Lizzy},
  title = {Looking Beyond Metastasis to Explain Cancer Death},
  journal = {Oncology Times},
  year = {2026},
  volume = {48},
  number = {3},
  pages = {15--15},
  doi = {10.1097/01.cot.0000000000000307}
}
Kostenlos starten →